About Msd Pharmaceuticals Private Limited
Data last updated: 22 December 2025
Msd Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India, a subsidiary of Merck Sharp & Dohme B.V.. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 03 December 2004, the company has been in operation for over 22 years.
Registered with ROC Delhi under CIN U24230DL2004PTC164459.
Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹13.2 Cr. It is led by directors Rehan Khan Abbas and Chand Berry.
Last AGM: 29 August 2025. Financial statements filed for year ended 31 March 2025. Office: 1544 Level 15 Eros Corporate Towers Nehru Place, New Delhi, Delhi, India – 110019.
As per the financials filed for FY 2025, the company reported a revenue of ₹2,748.9 Cr, a growth of 35% compared to the previous year.
The company has a workforce of approximately 1,146 employees as per the latest available data. It operates as a subsidiary of Merck Sharp & Dohme B.V..
The company is associated with 1 brand - Merck Sharp & Dohme.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website msdindia.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address1544 Level 15 Eros Corporate Towers Nehru Place, New Delhi, Delhi, India – 110019
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Msd Pharmaceuticals Private Limited
Msd Pharmaceuticals Private Limited has one previous CIN (Corporate Identification Number): U24230MH2004PTC149814. The current CIN is U24230DL2004PTC164459, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230DL2004PTC164459 | Current |
| U24230MH2004PTC149814 | Previous |
Associated Brands with Msd Pharmaceuticals Private Limited
Msd Pharmaceuticals Private Limited operates one associated brand: Merck Sharp & Dohme. These brands represent Msd Pharmaceuticals Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Therapies for HIV, cancer, diabetes, and infectious diseases are developed. | msd.com |
Competitors & Alternatives of Msd Pharmaceuticals Private Limited
Brands and companies operating in the same space as Msd Pharmaceuticals Private Limited include Jazz Pharmaceuticals, C4 Therapeutics, Erasca and 4 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jazz Pharmaceuticals
|
Novel biopharmaceutical medicines are developed for unmet medical needs. | Dublin, Ireland, Ireland | 2003 |
C4 Therapeutics
|
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | Cambridge, United States, United States | 2016 |
Erasca
|
Small molecule therapeutics for cancer treatment are developed. | San Diego, United States, United States | 2018 |
Nimbus Therapeutics
|
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | Cambridge, United States, United States | 2009 |
Avidity Biosciences
|
Antibody-siRNA complexes are developed for cancer treatment. | San Diego, United States, United States | 2012 |
Mereo BioPharma
|
Therapeutics for cancer and rare diseases are developed. | London, United Kingdom, United Kingdom | 2015 |
MiRagen
|
MicroRNA-based therapeutics are developed for treating multiple diseases. | Boulder, United States, United States | 2007 |
Business Activity of Msd Pharmaceuticals Private Limited
Msd Pharmaceuticals Private Limited is engaged in the principal business activity of trade, with detailed activities including retail trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G2 | Retail Trading | ********* |
Auditor Details of Msd Pharmaceuticals Private Limited
Msd Pharmaceuticals Private Limited is audited by Lovelock & Lewes Chartered Accountants LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Lovelock & Lewes Chartered Accountants LLP | blur-value | blur-value | blur-value |
Board of Directors of Msd Pharmaceuticals Private Limited
Msd Pharmaceuticals Private Limited is currently managed by 3 directors, with 19 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Rehan Khan Abbas
Also directs:
Metropolis Healthcare Limited, Msd Pharmaceuticals Private Limited
|
Managing Director | 07 May 2021 | 5 Years 2 Months | Current |
| Chand Berry | Whole-Time Director | 30 Sep 2021 | 4 Years 9 Months | Current |
Financials of Msd Pharmaceuticals Private Limited FY 2025 filings available
Msd Pharmaceuticals Private Limited reported revenue of ₹2,748.9 Cr (up 35% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Msd Pharmaceuticals Private Limited
As of FY 2023, Msd Pharmaceuticals Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings Msd Pharmaceuticals Private Limited
Msd Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Msd Pharmaceuticals Private Limited
Msd Pharmaceuticals Private Limited has a workforce of 1,146 employees as of Mar 31, 2024.
Employee Count & EPFO Data of Msd Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Msd Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Msd Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Msd Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Msd Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Msd Pharmaceuticals Private Limited
MSME Payment Delays by Msd Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Msd Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Msd Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Msd Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Msd Pharmaceuticals Private Limited
MCA Filings & Documents of Msd Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Msd Pharmaceuticals Private Limited
Recent News on Msd Pharmaceuticals Private Limited
Frequently Asked Questions about Msd Pharmaceuticals Private Limited
Msd Pharmaceuticals Private Limited is an active private limited company in the pharma sector based in New Delhi, Delhi, India. It was incorporated on 03 December 2004 (22+ years old) and is registered under CIN U24230DL2004PTC164459. The company has 1,146 employees.
Msd Pharmaceuticals Private Limited reported revenue of ₹2,748.9 Cr for FY 2025 (up 35.00% YoY).
The current directors of Msd Pharmaceuticals Private Limited are:
- Satinder Jeet Kaur
- Rehan Khan Abbas
- Chand Berry
The primary industry of Msd Pharmaceuticals Private Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Msd Pharmaceuticals Private Limited can be reached at the registered office: 1544 Level 15 Eros Corporate Towers Nehru Place, New Delhi, Delhi, India – 110019, or through the website msdindia.in.
The authorised capital is ₹15 Cr, and the paid-up capital is ₹13.2 Cr.